Compare CDT & EZRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDT | EZRA |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.4M |
| IPO Year | N/A | N/A |
| Metric | CDT | EZRA |
|---|---|---|
| Price | $8.36 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.7K | ★ 2.0M |
| Earning Date | 05-14-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.15 |
| 52 Week High | $11.00 | $0.39 |
| Indicator | CDT | EZRA |
|---|---|---|
| Relative Strength Index (RSI) | 95.36 | 40.24 |
| Support Level | $0.92 | $0.15 |
| Resistance Level | N/A | $0.22 |
| Average True Range (ATR) | 0.37 | 0.02 |
| MACD | 0.77 | -0.00 |
| Stochastic Oscillator | 71.73 | 10.38 |
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.